Supernus Pharma (SUPN) Tops Q3 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Supernus Announces Third Quarter 2014 Results
November 11, 2014 4:30 PM ESTThe Company raises revenue guidance from approximately $105 million to a range of $115 million to $118 million for 2014 and reaffirms cash flow break even by end of year. Total revenue for the quarter, $52.5 million, includes $30.0 million in royalty monetization revenue. Net product revenue for the third quarter for Trokendi XR® and Oxtellar XR® was $22.5 million. Third quarter product prescriptions increased to a total of 57,776, representing a 26% increase over the second quarter of 2014. Third quarter net income was $27.9 million. Excluding the $30 million royalty monetization payment, cash burn for the third quarter was $5 million, as compared to $8... More
